NSCLC tumors are resistant to drugs such as cisplatin and doxorubicin under hypoxia and normal conditions due to SirT1 downregulation, since H1299 and A549 cells expressing SirT1 had significantly lower IC50 values for cisplatin and doxorubicin, relative to those with SirT1 knocked down, revealing that SirT1 overexpression enhances drug sensitivity in NSCLC cells, while its knockdown confers resistance to anticancer drugs [383, 384]. The gene discussed is SIRT1; the disease is non-small cell lung carcinoma.